Tech Company Financing Transactions

Terns Pharmaceuticals Funding Round

On 1/6/2021, Terns Pharmaceuticals raised $87 million in Series C funding from Deerfield Capital, Eli Lilly and Company and Lilly Asia Ventures.

Transaction Overview

Announced On
1/6/2021
Transaction Type
Venture Equity
Amount
$87,000,000
Round
Series C
Proceeds Purpose
Terns plans to use the proceeds to advance clinical trials across its NASH pipeline and anticipates the following clinical milestones for its three lead NASH programs: TERN-101; TERN-201 and TERN-501.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1065 East Hillsdale Blvd. 100
Foster City, CA 94404
USA
Email Address
Overview
Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China.
Profile
Terns Pharmaceuticals LinkedIn Company Profile
Social Media
Terns Pharmaceuticals Company Twitter Account
Company News
Terns Pharmaceuticals News
Facebook
Terns Pharmaceuticals on Facebook
YouTube
Terns Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Senthil Sundaram
  Senthil Sundaram LinkedIn Profile  Senthil Sundaram Twitter Account  Senthil Sundaram News  Senthil Sundaram on Facebook
Chief Financial Officer
Mark Vignola
  Mark Vignola LinkedIn Profile  Mark Vignola Twitter Account  Mark Vignola News  Mark Vignola on Facebook
Chief Medical Officer
Erin Quirk
  Erin Quirk LinkedIn Profile  Erin Quirk Twitter Account  Erin Quirk News  Erin Quirk on Facebook
Chief Operating Officer
Bryan Yoon
  Bryan Yoon LinkedIn Profile  Bryan Yoon Twitter Account  Bryan Yoon News  Bryan Yoon on Facebook
Chief Scientific Officer
Weidong Zhong
  Weidong Zhong LinkedIn Profile  Weidong Zhong Twitter Account  Weidong Zhong News  Weidong Zhong on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/6/2021: Ikena Oncology venture capital transaction
Next: 1/6/2021: AiVita Biomedical venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary